Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - ethinylestradiol 35 µg; cyproterone acetate 2 mg - cyproterone and estrogen

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited- women’s health care plot no.564/a/22 road no.92, jubilee hills - cyproterone acetate bp ethinylestradiol bp - tablet - cyproterone acetate bp 2mg ethinylestradiol bp… - combinations of antiandrogens and estrogens

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: povidone; calcium carbonate; maize starch; sucrose; lactose monohydrate; macrogol 6000; purified talc; magnesium stearate; glycol montanate - diane-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. diane-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: macrogol 6000; lactose monohydrate; sucrose; povidone; purified talc; calcium carbonate; glycol montanate; maize starch; magnesium stearate - juliet-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis. the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. juliet-35 ed will also provide effective oral contraception in this patient group. if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: maize starch; calcium carbonate; purified talc; sucrose; glycol montanate; macrogol 6000; povidone; lactose monohydrate; magnesium stearate; glyceryl montanate - brenda-35 ed is indicated for the treatment of signs of androgenisation in women such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree.,brenda-35 ed will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent, the cause (i.e. androgen-producing tumour or an adrenal enzyme defect) must be clarified by differential diagnosis.

Malta - English - Medicines Authority

stragen uk limited castle court 41, london road, reigate, surrey, rh2prj, united kingdom - cyproterone acetate, ethinylestradiol - coated tablet - cyproterone acetate 2 mg ethinylestradiol 35 µg - sex hormones and modulators of the genital system

Canada - English - Health Canada

aa pharma inc - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cyproterone acetate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - cyproterone acetate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - cyproterone acetate - oral tablet - 50mg